PRQR
ProQR Therapeutics N.V.
NASDAQ · Healthcare · Biotechnology · NL
$2.07
−0.96%Year over year
Reported trailing growth
- Revenue
- +12.7%
- EBITDA
- -8.1%
- EBIT
- -3.3%
- EPS
- +7.8%
- Free cash flow
- -17.1%
- Operating cash flow
- -16.4%
Forward estimates
Based on analyst estimates
- Revenue
- -24.1%
- EBITDA
- -28.9%
- EPS
- -18.2%
Three-year CAGR
- Revenue
- +62.0%
- EBITDA
- -53.5%
- EBIT
- -38.3%
- Net income
- -45.9%
- EPS
- -11.8%
- Free cash flow
- -42.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026